Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Cancers|November 25, 2023
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of InterestBoaz Nachmias, Svetlana Krichevsky, Moshe E Gatt, et al.
Leukemia & Lymphoma|January 29, 2019
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapseNeta Goldschmidt, Netanel A Horowitz, Vered Heffes, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2016
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapyNeta Goldschmidt, Geffen Kleinstern, Marina Orevi, et al.
Leukemia & Lymphoma|October 16, 2025
First case report of talquetamab use in AL amyloidosisNoa Gross Even-Zohar, Shlomzion Aumann, Adir Shaulov, et al.
American Journal of Hematology|November 3, 2016
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapyAdir Shaulov, Chezi Ganzel, Noam Benyamini, et al.
Acta Haematologica|October 2, 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the LiteratureEyal Lebel, Vladimir Vainstein, Paolo Milani, et al.
Haematologica|March 31, 2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaOrtal Harush, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Acta Haematologica|August 7, 2022
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid LeukemiaBoaz Nachmias, Svetlana Krichevsky, Dvora Filon, et al.
Haematologica|June 29, 2023
Amyloidogenic light chains impair plasma cell survivalMarjorie Pick, Eyal Lebel, Sharona Elgavish, et al.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
Pageof 9